General Information of Drug (ID: DM37RI9)

Drug Name
1-(3-Phenyl-propyl)-3-thiazol-2-yl-thiourea
Synonyms
Thiourea, N-(3-phenylpropyl)-N'-2-thiazolyl-; 149485-04-1; AC1MHDKJ; SCHEMBL6959149; CHEMBL145260; DTXSID10164283; AYXFDRTXLUHLOL-UHFFFAOYSA-N; ZINC12354016; AKOS030030954; N-(3-Phenylpropyl)-N'-(2-thiazolyl)thiourea; 1-(3-phenylpropyl)-3-thiazol-2-yl-thiourea; N-(3-Phenylpropyl)-N'-(2-thiazolyl) thiourea
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 277.4
Topological Polar Surface Area (xlogp) 3.2
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
Chemical Identifiers
Formula
C13H15N3S2
IUPAC Name
1-(3-phenylpropyl)-3-(1,3-thiazol-2-yl)thiourea
Canonical SMILES
C1=CC=C(C=C1)CCCNC(=S)NC2=NC=CS2
InChI
InChI=1S/C13H15N3S2/c17-12(16-13-15-9-10-18-13)14-8-4-7-11-5-2-1-3-6-11/h1-3,5-6,9-10H,4,7-8H2,(H2,14,15,16,17)
InChIKey
AYXFDRTXLUHLOL-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3001100
CAS Number
149485-04-1
TTD ID
D0B8FZ

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
2 Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
3 HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
4 A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
7 Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
8 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.